Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis

ConclusionPembrolizumab plus axitinib seemed to be the most efficacious first-line agents, while nivolumab plus ipilimumab had the most favorable efficacy –tolerability equilibrium. These findings may facilitate individualized treatment strategies and inform future direct comparative trials in an expanding treatment options without direct comparison between approved drugs.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research